In less than a month, thousands of people will gather at AIDS 2024, the 25th International AIDS Conference, in Munich, Germany, and virtually to share knowledge, best practices and lessons learnt from the HIV response. Here is a preview of HIV treatment and cure research highlights you can expect.
Some HIV treatment and cure research highlights to expect at AIDS 2024
- An update from the ARTISTRY-1 study, which is evaluating bictegravir plus lenacapavir in virologically suppressed people with HIV who are otherwise unable to take a single-tablet regimen
- An analysis of emerging dolutegravir resistance in children and adolescents living with HIV in Malawi
- Extended week 96 analysis data from the D2EFT trial on the extended efficacy and safety of dolutegravir- and darunavir- containing regimens
- A study showing that PD-1 blockade combined with therapeutic vaccination leads to sustained suppression of SIV following ART discontinuation in macaques
- A novel approach to treat HIV reservoirs in gut-associated lymphoid tissues using nanoformulations of combination antiretroviral therapy drugs
AIDS 2024 late-breaker abstracts are now also available in the programme.
